Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.65 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.65 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.56 |
| ▸ | BHMT | Q93088 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 6/20 | 0.44 |
| ▸ | PPARD | Q03181 | 6/20 | 0.44 |
| ▸ | PPARA | Q07869 | 6/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8176355 | 0.95 | GPR84 (0.73) | GPR84FFAR1FFAR4CAMK2ABHMT | |
| SCHEMBL8650879 | 0.95 | GPR84 (0.73) | GPR84FFAR1FFAR4CAMK2ABHMT | |
| SCHEMBL8650019 | 0.95 | GPR84 (0.73) | GPR84FFAR1FFAR4CAMK2ABHMT | |
| SCHEMBL9262544 | 0.95 | GPR84 (0.73) | GPR84FFAR1FFAR4CAMK2ABHMT | |
| SCHEMBL9264906 | 0.95 | GPR84 (0.73) | GPR84FFAR1FFAR4CAMK2ABHMT | |
| SCHEMBL8651227 | 0.95 | GPR84 (0.73) | GPR84FFAR1FFAR4CAMK2ABHMT | |
| SCHEMBL18771046 | 0.91 | GPR84 (0.58) | GPR84FFAR1FFAR4CAMK2ABHMT | |
| SCHEMBL17822696 | 0.91 | GPR84 (0.58) | GPR84FFAR1FFAR4CAMK2ABHMT | |
| SCHEMBL7509590 | 0.91 | CAMK2A (0.62) | GPR84FFAR1FFAR4CAMK2ABHMT | |
| SCHEMBL7692824 | 0.91 | TSHR (0.67) | GPR84FFAR1FFAR4BHMTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-10-31 | — | — | US | disclosed |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2024-07-30 | — | — | US | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114502172-A | Nucleoside prodrugs and related uses thereof | 爱默蕾大学 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021035214-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2021-02-25 | — | — | WO | disclosed |
| US-10010629-B2 | Compositions and methods for in vivo imaging | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-03 | — | — | US | disclosed |
| US-20150343094-A1 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-12-03 | — | — | US | disclosed |
| WO-2011146390-A2 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | GPR84 1083/4885FFAR1 201/4885FFAR4 250/4885 |
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | GPR84 1083/4885FFAR1 201/4885FFAR4 250/4885 |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | PNPO, GSTO1, CYP2C18 | GPR84 1083/4885FFAR1 201/4885FFAR4 250/4885 |
| US-20150343094-A1 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING | PLIN3, SGMS1, SGMS2 | GPR84 1125/4885FFAR1 78/4885FFAR4 77/4885 |
| US-10010629-B2 | Compositions and methods for in vivo imaging | PLIN3, SGMS1, SGMS2 | GPR84 1125/4885FFAR1 78/4885FFAR4 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.